The primary objective of the Biostatistics Core in this P01 is to facilitate the understanding of the biology of melanomas and the development of novel strategies for melanoma treatment based on the most stringent and highest quality of statistical data analyses and inferences. The Biostatistics Core is well organized and equipped to achieve this goal. This Core will provide expertise on experimental design and critical analytical services to Investigators that are tailored to each project and provided in a timely and cost-effective manner. The biostatisticians in this Core will meet regularly with project investigators to develop analytic strategies, assess the statistical needs for each particular project on an ongoing basis, and to modify analysis plans as the research evolves. Since many elements of the statistical analysis plans will be specific to a particular study, each project will benefit from the centralized resource, including individuals who can provide expertise in study design, biostatistics methodology and specialized data analysis techniques and who have had significant experience in solving statistical issues in biological cancer research. This level of collaboration between Core biostatisticians and project Investigators will ensure that the quality and validity of each research project will be of the highest degree. In addition to the statistical services provided to each project, this Core is the essential centralized resource to integrate the data across all projects in this program and synthesize study findings. Using state of the art statistical techniques combined with high-throughput data garnered from each project, the Core will provide a clear and complete view of the associations between studied inhibitors and genotypes, and provide quantitative assessment regarding the development of novel strategies of melanoma treatment in this P01

Public Health Relevance

This Core is pivotal to ensure that the experimental design and data analyses within the Projects are done in a rigorous, integrated fashion, and to forge new directions in the translational components of the Program Project. This Core has a wealth of experience in cancer research that is used by the Program Project. The quantitative data analyses done by the Core allow us to better understand the associations between the studied inhibitors and genotypes of melanoma, as well as mechanisms of various combination therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA114046-07
Application #
8759680
Study Section
Special Emphasis Panel (ZCA1-RPRB-2)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
7
Fiscal Year
2014
Total Cost
$128,040
Indirect Cost
$36,661
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Pathria, Gaurav; Scott, David A; Feng, Yongmei et al. (2018) Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J 37:
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Kaur, Amanpreet; Ecker, Brett L; Douglass, Stephen M et al. (2018) Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov :
Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Nti, Akosua A; Serrano, Leona W; Sandhu, Harpal S et al. (2018) FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina :

Showing the most recent 10 out of 144 publications